Company profile
Immunocore Holdings plc
NASDAQ:IMCRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| TEBENTAFUSP | phase3 | — | 7 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02570308 | phase1_2 | completed | 2016-02-29 | 2020-03-20 | Immunocore Ltd | A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma |
| NCT06112314 | phase3 | recruiting | 2024-06-05 | 2027-10-16 | Immunocore Ltd | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) |
| NCT02889861 | phase2 | terminated | 2017-01-11 | 2019-04-22 | Immunocore Ltd | IMCgp100-401 Rollover Study |
| NCT06840119 | phase1_2 | recruiting | 2024-01-10 | 2026-11-30 | Immunocore Ltd | Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers |
| NCT02535078 | phase1_2 | withdrawn | 2015-11-01 | 2023-06-19 | Immunocore Ltd | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761228 | BLA | Immunocore Limited | ||||
Loading… | ||||||